Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhPro-UK vs Alteplase in Acute Ischemic Stroke
NCT03541668Phase 3Completed
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
- Start
- May 2018
- Primary completion
- Apr 2020
- Modality
- Metabolic Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of recombinant human prourokinase in ischemic stroke (2 arms), sponsored by Tasly Biopharmaceuticals Co., Ltd. Primary endpoint: Functional Handicap (Modified Rankin Scale score 0-1) at 90 days. Started May 2018; status: completed.
02
Drugs
recombinant human prourokinase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03541668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03541668.